JTV-519 NEW
| Price | $55 | $112 | $157 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: JTV-519 | CAS No.: 1038410-88-6 |
| Purity: 99.8% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | JTV-519 |
| Description | JTV-519 is a Ca2+-dependent blocker and prevents abnormal Ca(2+) leak from the sarcoplasmic reticulum in the ischemic heart and skeletal muscle (SkM) by stabilizing the ryanodine receptors. |
| In vitro | In isolated cardiac and SkM SR microsomes, K201 slowed the rate of SR Ca(2+) loading, suggesting potential SERCA block and/or RyR agonism. K201 displayed Ca(2+)-dependent inhibition of SERCA-dependent ATPase activity, which was measured in microsomes incubated with 200, 2, and 0.25 μM Ca(2+) and with the half-maximal K201 inhibitory doses (IC50) estimated at 130, 19, and 9 μM (cardiac muscle) and 104, 13, and 5 μM (SkM SR). K201 (≥5 μM) increased RyR1-mediated Ca(2+) release from SkM microsomes. Maximal K201 doses at 80 μM produced ～37% of the increase in SkM SR Ca(2+) release observed with the RyR agonist caffeine. K201 (≥5 μM) increased the open probability (Po) of very active ('high-activity') RyR1 of SkM reconstituted into bilayers, but it had no effect on 'low-activity' channels. Likewise, K201 activated cardiac RyR2 under systolic Ca(2+) conditions (～5 μM; channels at Po ～0.3) but not under diastolic Ca(2+) conditions (～100 nM; Po < 0.01)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 25 mg/mL (54.22 mM) |
| Keywords | K201 | JTV519 |
| Inhibitors Related | Nisoldipine | Nimodipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | Lanthanum(III) chloride heptahydrate | Ethyl cinnamate | 1-Octanol | 2-Nitrobenzoic acid | 1,2,4-Trihydroxybenzene | Methyl homoveratrate | Otilonium bromide |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $9.50/20mg |
NanJing Spring & Autumn Biological Engineering CO., LTD.
|
2019-07-11 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY